Conclusion of non-exclusive discount agreements according to § 130 a Abs. 8 SGB V with the possibility of conclusion at any time within the framework of so-called "OpenHouse procedure" for various active pharmaceutical ingredients with the earliest possible start of the contract on 01.10.2022.
,
The specific active pharmaceutical ingredients and the respective contract starts can be found in the current list of active pharmaceutical ingredients in the project area of the dtvp procurement portal under the heading "Procurement documents".
,
As of 01.10.2022, contracts will be offered for the following active ingredients:
,
Abacavir / Lamivudin / Zidovudin
Acetylcystein_non-RX non-RX
Acetylcystein_RX RX
Acetylsalicylic acid only prescription products according to Appendix 1 AM-RL G-BA
Acitretin
adefovir dipivoxil
Alitretinoin
Amifampridine
Anagrelide excluding N3 packs of DAR ICP with 0.5 mg potency
Aripiprazole excluding DAR tablets/orodispersible tablets and oral solutions
Atorvastatin/Ezetimib
Beclometasone/Formoterol
Beclometasone/Formoterol/Glycopyrronium
bimatoprost
Biperids
Bortezomib
Brivudine
Budesonide excluding inhalatives
Calcipotriol
Calcium / Colecalciferol
Ceftriaxone
Clomipramine 75 mg potency, retarded
Clostridium botulinum excluding lifestyle medicines
Non-RX cholecalciferol
Cholecalciferol RX
Colistin
Cyproterone
Deferasirox
Desloratadine
Desogestrel / Ethinylestradiol
Dienogest
Dienogest / Ethinylestradiol
Diltiazem
distigmine
Dornase alpha
Dronedaron
Drospirenon / Ethinylestradiol
ebastine
Iron II oral DAR/only products eligible for prescription according to Appendix 1 AM-RL G-BA
Enoxaparin 20 mg and 40 mg 20 mg and 40 mg potency
Enoxaparin 60 mg, 80 mg and 100 mg 60 mg, 80 mg and 100 mg potency
Ertugliflozin
Erythropoietin Epoetin
Eslicarbazepine
Estradiol
Etanercept
Etravirine
Everolimus
fampridine
fentanyl
Filgrastim
Flupentixol decanoat
Follitropin alfa
follitropin beta
Fondaparinux sodium
fusidic acid
Fusidinsäure / Betamethason
Glatiramer acetate (40mg potency DAR PEN)
Goserelin
hydrocortisone
Hydromorphone DAR solution for injection/infusion
Hydroxychloroquine
Hydroxyzine
Ibuprofen (non-RX, liquid oral dosage forms)
Ibuprofen (RX 400mg and 600mg)
Ibuprofen (RX 800 mg retardiert)
Ibuprofen (RX 800mg not retarded)
imatinib
Infliximab
Interferon beta 1a Avonex(R)
Interferon beta 1a Rebif(R)
Lanreotide
lenalidomide
Lenograstim
Leuprorelin
Lidocaine DAR Patch
Lipegfilgrastim
Loperamid
Lopinavir / Ritonavir
Macrogol only products that can be prescribed in accordance with Annex 1 AM-RL G-BA
Macrogol only medical devices that can be prescribed in accordance with Annex 5 AM-RL G-BA
Meloxicam
Meropenem
Methocarbamol excluding DAR film-coated tablets with 750 mg active ingredient strength
Metoclopramide
Midazolam
Minocycline
Nadroparin
Natalizumab excluding subcutaneous use
Nitisinone
Octreotide
Olmesartan / Amlodipin / HCT
Oxycodone / Naloxone
Paliperidone
Palonosetron
Pankreatin
Paracetamol only products that can be prescribed in accordance with Annex 1 AM-RL G-BA
Pegfilgrastim
peginterferon beta-1a
Pemetrexed
Perindopril / Indapamid
Perindopril/ Amlodipine
Promethazine
Pyridostigmine
rabeprazole
Raltegravir
Risperidone only dry substances with solvents and powders and solvents for solution for injection
ritonavir
Rituximab
Roflumilast
Rosuvastatin/Ezetimib
Rotigotine
Rupatadin
Silodosin
Somatropin
Sorafenib
Sulfasalazine
Sunitinib
Tacrolimus
Tadalafil exclusively indication BPH
Tapentadol
Teriparatide
Timolol / Bimatoprost DAR eye drops in single dose container
Tiotropium bromide Inh.lsg
Tobramycin
Tolvaptan
Tramadol / Paracetamol
Trastuzumab
Travoprost / Timolol
Triptorelin
zidovudine
Zolmitriptan
,
The contracts end uniformly on 30.09.2024.
AOK Rheinland/Hamburg announces the conclusion of non-exclusive discount agreements in accordance with § 130 a (8) SGB V with the possibility of conclusion at any time within the framework of the so-called "OpenHouse procedure" for various active pharmaceutical ingredients with the earliest possible start of the contract on 01.10.2022.
,
The specific active pharmaceutical ingredients and the respective, earliest possible contract starts can be found in the current list of active pharmaceutical ingredients in the project area of the dtvp procurement portal under the heading "Procurement documents".
,
Providing uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies are offered the conclusion or entry to a discount contract in accordance with Section 130a (8) SGB V.
,
Interested pharmaceutical companies can obtain the participation documents in the project room of the DTVP procurement portal under the heading "Procurement documents".
,
The prerequisite for the conclusion of a contract is that the interested pharmaceutical company sends the requested participation documents completely completed and signed to the following e-mail inbox:
,
open-house@rh.aok.de.
,
This e-mail inbox is used for any exchange of documents and documents for the implementation of the OpenHouse procedure between the companies and the medicinal products division of AOK Rheinland/Hamburg.
,
A contract is concluded with every pharmaceutical company that meets the eligibility requirements. There is no exclusivity. The accession or the conclusion of the contract can take place at any time and under the same conditions. Individual contract negotiations are not conducted.
,
The earliest start of the contract is 01.10.2022. The conclusion or accession to a discount contract is possible at any time, i.e. even after 01.10.2022. The contract period ends uniformly on 30.09.2024, regardless of the individual start of the contract.
,
The list of the contractually active substances is changed at irregular intervals. In this case, all companies verified in the project room in the DTVP award portal will receive an email with information about which active ingredients have been added and when the earliest possible start of the contract is.
Should AOK Rheinland/Hamburg carry out a tender for exclusive contracts in the form of an EU-wide, open procedure during the term of the contract, the contracts concluded within the framework of this publication will be terminated in accordance with the contractual provisions.
,
This publication is not about awarding a public contract within the meaning of the public procurement coordination directive (2014/24 / EG) or public procurement law. In order to ensure the highest level of transparency for the intended contracts, the publication is published in the supplement to the Official Journal of the European Union. In the absence of a corresponding publication form, the contract notice will be used.
,
The resulting conceptual requirements, such as the procedure designation "open procedure", are solely due to the use of this announcement form and the publication platform. A further significance, in particular a submission to procurement law regulations, insofar as they are not obliged for legal reasons, is not associated with this.